Olivia M. Farr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Olivia M. Farr has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Christos S. Mantzoros
Division of Endocrinology, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 02215, United States of America; Section of Endocrinology, Boston VA Healthcare System/Harvard Medical School, Boston, MA 02130, United States of America
20 shared publications- Christos Socrates Mantzoros
Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
11 shared publications Sien Hu
Department of Psychiatry, Yale University School of Medicine New Haven, CT, USA
9 shared publicationsSheng Zhang
Department of Psychiatry, Yale University School of Medicine New Haven, CT, USA
7 shared publications- Chiang-Shan Ray Li
Department of Psychiatry Yale University School of Medicine New Haven Connecticut USA
6 shared publications - Michael A. Tsoukas
Department of Medicine McGill University Montreal Quebec Canada
6 shared publications
Latest Publications
- 15 February 2021
- Published by SAGE Publications in Nutrition and Health
- Vol. 27 (3) , 295-299
Acute diet soda consumption alters brain responses to food cues in humans: A randomized, controlled, cross-over pilot study
Background: Diet soda consumption has frequently been linked to obesity and its comorbidities in epidemiological studies. Whether this link is causal and a potential mechanism remains to be determined. Aim/Methods: This randomized, cross-over, controlled pilot study sought to determine whether there may be changes in reward-related brain activations to visual food cues after acute consumption of diet soda versus regular soda or carbonated water using functional magnetic resonance imaging. Results: Diet soda as compared to carbonated water consumption increased activation of reward-related caudate to highly versus less desirable food cues. Diet soda as compared to regular soda increased reward-related insula and decreased activation of cognitive control-related dorsolateral prefrontal cortex to food cues versus non-food cues. No changes in ratings of hunger an hour after beverage consumption were observed. Conclusions: These results may suggest a potential mechanism for diet soda to increase food palatability through activation of the reward system and suppression of inhibitory control that remains to be confirmed by future studies.
- 15 February 2021
- Published by SAGE Publications in Nutrition and Health
- Vol. 27 (3) , 295-299
Acute diet soda consumption alters brain responses to food cues in humans: A randomized, controlled, cross-over pilot study
Background: Diet soda consumption has frequently been linked to obesity and its comorbidities in epidemiological studies. Whether this link is causal and a potential mechanism remains to be determined. Aim/Methods: This randomized, cross-over, controlled pilot study sought to determine whether there may be changes in reward-related brain activations to visual food cues after acute consumption of diet soda versus regular soda or carbonated water using functional magnetic resonance imaging. Results: Diet soda as compared to carbonated water consumption increased activation of reward-related caudate to highly versus less desirable food cues. Diet soda as compared to regular soda increased reward-related insula and decreased activation of cognitive control-related dorsolateral prefrontal cortex to food cues versus non-food cues. No changes in ratings of hunger an hour after beverage consumption were observed. Conclusions: These results may suggest a potential mechanism for diet soda to increase food palatability through activation of the reward system and suppression of inhibitory control that remains to be confirmed by future studies.
- Open Access
- 8 January 2021
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (5) , 1202-1207
Fasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward‐ and attention‐related brain centres in response to visual food cues in adults with obesity: A cross‐sectional functional MRI study
Postprandial increases in gastrointestinal hormones are associated with reduced energy intake, partially through direct effects on the brain. However, it remains unknown whether the fasting levels of gastrointestinal hormones are associated with altered brain activity in response to visual food stimuli. We therefore performed a whole‐brain regression cross‐sectional analysis to assess the association between fasting brain activations according to functional magnetic resonance imaging, performed during viewing of highly desirable versus less desirable food images, with fasting levels of five gastrointestinal hormones (glucagon‐like peptide [GLP]‐1, GLP‐2, oxyntomodulin, glicentin and gastric inhibitory polypeptide [GIP]) in 36 subjects with obesity. We observed that fasting blood levels of GIP were inversely associated with the activation of attention‐related areas (visual cortices of the occipital lobe, parietal lobe) and of oxyntomodulin and glicentin with reward‐related areas (insula, putamen, caudate for both, and additionally orbitofrontal cortex for glicentin) and the hypothalamus when viewing highly desirable as compared to less desirable food images. Future studies are needed to confirm whether fasting levels of oxyntomodulin, glicentin and GIP are associated with the activation of brain areas involved in appetite regulation and with energy intake in people with obesity.
- 8 January 2021
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 23 (5) , 1202-1207
Open AccessFasting oxyntomodulin, glicentin, and gastric inhibitory polypeptide levels are associated with activation of reward‐ and attention‐related brain centres in response to visual food cues in adults with obesity: A cross‐sectional functional MRI study
Postprandial increases in gastrointestinal hormones are associated with reduced energy intake, partially through direct effects on the brain. However, it remains unknown whether the fasting levels of gastrointestinal hormones are associated with altered brain activity in response to visual food stimuli. We therefore performed a whole‐brain regression cross‐sectional analysis to assess the association between fasting brain activations according to functional magnetic resonance imaging, performed during viewing of highly desirable versus less desirable food images, with fasting levels of five gastrointestinal hormones (glucagon‐like peptide [GLP]‐1, GLP‐2, oxyntomodulin, glicentin and gastric inhibitory polypeptide [GIP]) in 36 subjects with obesity. We observed that fasting blood levels of GIP were inversely associated with the activation of attention‐related areas (visual cortices of the occipital lobe, parietal lobe) and of oxyntomodulin and glicentin with reward‐related areas (insula, putamen, caudate for both, and additionally orbitofrontal cortex for glicentin) and the hypothalamus when viewing highly desirable as compared to less desirable food images. Future studies are needed to confirm whether fasting levels of oxyntomodulin, glicentin and GIP are associated with the activation of brain areas involved in appetite regulation and with energy intake in people with obesity.
- 9 November 2019
- Published by Elsevier in Metabolism
- Vol. 102, 154009
Metabolism updates: new directions, techniques, and exciting research that is broadening the horizons
- 9 November 2019
- Published by Elsevier in Metabolism
- Vol. 102, 154009
Metabolism updates: new directions, techniques, and exciting research that is broadening the horizons
- 1 October 2019
- Published by Elsevier in Metabolism
- Vol. 99, III-VIII
Old and new tools to study human brain physiology: Current state, future directions and implications for metabolic regulation
- 1 October 2019
- Published by Elsevier in Metabolism
- Vol. 99, III-VIII
Old and new tools to study human brain physiology: Current state, future directions and implications for metabolic regulation
- 7 July 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (11) , 2459-2464
Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies
Aims: GLP‐1 analogs have recently risen to the forefront as effective medications for lowering weight through actions in the central nervous system (CNS). However, their actions in the CNS have not yet been studied in the human brain after longer‐term administration at the highest dose approved for obesity (liraglutide 3.0 mg). Materials and Methods: A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo‐controlled, double‐blind, cross‐over trial after 5 weeks of dose escalation. Neurocognitive and neuroimaging (fMRI) responses to food cues were examined at the clinical research center of Beth Israel Deaconess Medical Center. Results: While using liraglutide, patients lost more weight (placebo‐subtracted −2.7%; P < .001), had decreased fasting glucose ( P < .001) and showed improved cholesterol levels. In an uncontrolled analysis, brain activation in response to food images was not altered by liraglutide vs placebo. When controlled for BMI/weight, liraglutide increased activation of the right orbitofrontal cortex (OFC) in response to food cues ( P < .016, corrected for multiple comparisons). Conclusions: In contrast to prior studies, we demonstrate for the first time that liraglutide treatment, administered over a longer period at the highest doses approved for obesity, does not alter brain activation in response to food cues. A counter‐regulatory increase in reward‐related OFC activation in response to food cues can be observed when neuroimaging data are controlled for BMI changes, indicating changes in CNS that could lead to later plateaus of weight loss. These data point to a promising focus for additional interventions which, by contributing to the CNS reward system, could provide tangible benefits in reversing the plateauing phenomenon and promoting further weight loss.
- 7 July 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (11) , 2459-2464
Longer‐term liraglutide administration at the highest dose approved for obesity increases reward‐related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti‐obesity therapies
Aims: GLP‐1 analogs have recently risen to the forefront as effective medications for lowering weight through actions in the central nervous system (CNS). However, their actions in the CNS have not yet been studied in the human brain after longer‐term administration at the highest dose approved for obesity (liraglutide 3.0 mg). Materials and Methods: A total of 20 participants with obesity were treated with placebo and liraglutide (3.0 mg) in the context of a randomized, placebo‐controlled, double‐blind, cross‐over trial after 5 weeks of dose escalation. Neurocognitive and neuroimaging (fMRI) responses to food cues were examined at the clinical research center of Beth Israel Deaconess Medical Center. Results: While using liraglutide, patients lost more weight (placebo‐subtracted −2.7%; P < .001), had decreased fasting glucose ( P < .001) and showed improved cholesterol levels. In an uncontrolled analysis, brain activation in response to food images was not altered by liraglutide vs placebo. When controlled for BMI/weight, liraglutide increased activation of the right orbitofrontal cortex (OFC) in response to food cues ( P < .016, corrected for multiple comparisons). Conclusions: In contrast to prior studies, we demonstrate for the first time that liraglutide treatment, administered over a longer period at the highest doses approved for obesity, does not alter brain activation in response to food cues. A counter‐regulatory increase in reward‐related OFC activation in response to food cues can be observed when neuroimaging data are controlled for BMI changes, indicating changes in CNS that could lead to later plateaus of weight loss. These data point to a promising focus for additional interventions which, by contributing to the CNS reward system, could provide tangible benefits in reversing the plateauing phenomenon and promoting further weight loss.
- 4 June 2019
- Published by Elsevier in Metabolism
- Vol. 98, 121-135
Of mice and men: incretin actions in the central nervous system
- 4 June 2019
- Published by Elsevier in Metabolism
- Vol. 98, 121-135
Of mice and men: incretin actions in the central nervous system
- 14 May 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (9) , 2086-2095
Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross‐over, randomized, double‐blind, controlled inpatient physiology study
Aims: To assess the effects of walnuts on cardiometabolic outcomes in obese people and to explore the underlying mechanisms using novel methods including metabolomic, lipidomic, glycomic and microbiome analysis, integrated with lipid particle fractionation, appetite‐regulating hormones and haemodynamic measurements. Materials and Methods: A total of 10 obese individuals were enrolled in this cross‐over, randomized, double‐blind, placebo‐controlled clinical trial. The participants had two 5‐day inpatient stays, during which they consumed a smoothie containing 48 g walnuts or a macronutrient‐matched placebo smoothie without nuts, with a 1‐month washout period between the two visits. Results: Walnut consumption improved aspects of the lipid profile; it reduced fasting small and dense LDL particles ( P < 0.02) and increased postprandial large HDL particles ( P < 0.01). Lipoprotein insulin resistance score, glucose and the insulin area under the curve (AUC) decreased significantly after walnut consumption ( P < 0.01, P < 0.02 and P < 0.04, respectively). Consuming walnuts significantly increased 10 N‐glycans, with eight of them carrying a fucose core. Lipidomic analysis showed a robust reduction in harmful ceramides, hexosylceramides and sphingomyelins, which have been shown to mediate effects on cardiometabolic risk. The peptide YY AUC significantly increased after walnut consumption ( P < 0.03). No major significant changes in haemodynamic or metabolomic analysis or in microbiome host health‐promoting bacteria such as Faecalibacterium were found. Conclusions: These data provide a more comprehensive mechanistic perspective of the effect of dietary walnut consumption on cardiometabolic variables. Lipidomic and lipid nuclear magnetic resonance spectroscopy analysis showed an early but significant reduction in ceramides and other atherogenic lipids with walnut consumption, which may explain the longer‐term benefits of walnuts or other nuts on insulin resistance, cardiovascular risk and mortality.
- 14 May 2019
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 21 (9) , 2086-2095
Mechanisms underlying the cardiometabolic protective effect of walnut consumption in obese people: A cross‐over, randomized, double‐blind, controlled inpatient physiology study
Aims: To assess the effects of walnuts on cardiometabolic outcomes in obese people and to explore the underlying mechanisms using novel methods including metabolomic, lipidomic, glycomic and microbiome analysis, integrated with lipid particle fractionation, appetite‐regulating hormones and haemodynamic measurements. Materials and Methods: A total of 10 obese individuals were enrolled in this cross‐over, randomized, double‐blind, placebo‐controlled clinical trial. The participants had two 5‐day inpatient stays, during which they consumed a smoothie containing 48 g walnuts or a macronutrient‐matched placebo smoothie without nuts, with a 1‐month washout period between the two visits. Results: Walnut consumption improved aspects of the lipid profile; it reduced fasting small and dense LDL particles ( P < 0.02) and increased postprandial large HDL particles ( P < 0.01). Lipoprotein insulin resistance score, glucose and the insulin area under the curve (AUC) decreased significantly after walnut consumption ( P < 0.01, P < 0.02 and P < 0.04, respectively). Consuming walnuts significantly increased 10 N‐glycans, with eight of them carrying a fucose core. Lipidomic analysis showed a robust reduction in harmful ceramides, hexosylceramides and sphingomyelins, which have been shown to mediate effects on cardiometabolic risk. The peptide YY AUC significantly increased after walnut consumption ( P < 0.03). No major significant changes in haemodynamic or metabolomic analysis or in microbiome host health‐promoting bacteria such as Faecalibacterium were found. Conclusions: These data provide a more comprehensive mechanistic perspective of the effect of dietary walnut consumption on cardiometabolic variables. Lipidomic and lipid nuclear magnetic resonance spectroscopy analysis showed an early but significant reduction in ceramides and other atherogenic lipids with walnut consumption, which may explain the longer‐term benefits of walnuts or other nuts on insulin resistance, cardiovascular risk and mortality.
- 1 March 2019
- Published by Elsevier in Metabolism
- Vol. 92, 170-192
Pharmacotherapy of obesity: Available medications and drugs under investigation
- 1 March 2019
- Published by Elsevier in Metabolism
- Vol. 92, 170-192
Pharmacotherapy of obesity: Available medications and drugs under investigation